Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

Tolvaptan (TLV) was US Food and Drug Administration (FDA)‐approved for the indication to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease in 2018. In vitro, TLV was a breast cancer resistance protein (BCRP) inhibitor, whereas the oxob...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoaf, Susan E., Bricmont, Patricia, Repella Gordon, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301576/
https://www.ncbi.nlm.nih.gov/pubmed/33742787
http://dx.doi.org/10.1111/cts.13017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301576/
https://www.ncbi.nlm.nih.gov/pubmed/33742787
http://dx.doi.org/10.1111/cts.13017

Ejemplares similares